Please login to the form below

Not currently logged in

EU approval for Teva's contraceptive Zoely

Teva's new combined oral contraceptive Zoely has gained approval from the European Medicines Agency (EMA) for launch in the EU

Teva Pharmaceutical Industries gained approval today from the European Medicines Agency (EMA) for the launch of its new oral contraceptive, Zoely (nomegestrol acetate).

The drug is a combined oral contraceptive (COC), and once launched, will be available in a 24 day active and 4 day placebo dosing regimen. It is approved for use in the EU.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the drug in March, 2011, stating that there is a "favourable benefit to risk balance for Zoely." The CHMP is an advisory body to the EMA.

The approval of Zoely covers the 27 EU member States as well as Norway, Iceland and Liechtenstein, with Teva holding the exclusive marketing rights in France, Belgium and Spain. The first launch of Zoely is expected before the end of 2011.

2nd August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...